HDAC/JAK/BRD4-IN-1

• UNSPSC Description:

  HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor. HDAC/JAK/BRD4-IN-1 inhibit cell growth and induces apoptosis in MDA-MB-231 cells, and shows anticancer activity in vivo[1].

• Target Antigen:

  Apoptosis; Epigenetic Reader Domain; HDAC; JAK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-jak-brd4-in-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  ONC(C1=CC=C(C=C1)NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=O

• Molecular Weight:

  448.52

• References & Citations:

  [1]Zhao C, et al. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer [published online ahead of print, 2023 Oct 5]. J Med Chem. 2023;10.1021/acs.jmedchem.3c01242.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2755325-84-7